Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
Alessio CortelliniMassimo Di MaioOlga NigroAlessandro LeonettiDiego L CortinovisJoachim Gjv AertsGiorgia GuaitoliFausto BarbieriRaffaele GiustiMiriam G FerraraEmilio BriaEttore D'ArgentoFrancesco GrossiErika RijavecAnnalisa GuidaRossana BerardiMariangela TorniaiVincenzo SforzaCarlo GenovaFrancesca MazzoniMarina Chiara GarassinoAlessandro De TomaDiego SignorelliAlain GelibterMarco SiringoPaolo MarchettiMarianna MacerelliFrancesca RastelliRita ChiariDanilo RoccoLuigi Della GravaraAlessandro InnoDe Tursi MicheleAntonino GrassadoniaPietro Di MarinoGiovanni MansuetoFederica ZorattoMarco FilettiDaniele SantiniFabrizio CitarellaMarco RussanoLuca CantiniAlessandro TuziPaola BordiGabriele MinutiLorenza LandiSerena RicciardiMaria R MigliorinoFrancesco PassigliaPaolo BironzoGiulio MetroVincenzo AdamoAlessandro RussoGian Paolo SpinelliGiuseppe L BannaAlex FriedlaenderAlfredo AddeoKatia CannitaCorrado FicorellaGiampiero PorzioDavid James PinatoPublished in: Journal for immunotherapy of cancer (2021)
In this study, we validate the significant negative impact of ATB on pembrolizumab monotherapy but not chemotherapy outcomes in NSCLC, producing further evidence about their underlying immune-modulatory effect. Even though the magnitude of the impact of corticosteroids and PPIs is significantly different across the cohorts, their effects might be driven by adverse disease features.
Keyphrases
- advanced non small cell lung cancer
- locally advanced
- small cell lung cancer
- rectal cancer
- prostate cancer
- squamous cell carcinoma
- clinical trial
- randomized controlled trial
- radiation therapy
- emergency department
- stem cells
- open label
- radical prostatectomy
- metabolic syndrome
- adverse drug
- minimally invasive
- anti inflammatory
- smoking cessation
- electronic health record
- replacement therapy